We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Show more
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 –...
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.78 | 15.9355416294 | 11.17 | 13.59 | 11.17 | 156423 | 12.60800338 | CS |
4 | -0.0796 | -0.610916682016 | 13.0296 | 13.7499 | 10.37 | 125161 | 12.19334728 | CS |
12 | -1.2 | -8.48056537102 | 14.15 | 16.905 | 10.37 | 149903 | 13.57824631 | CS |
26 | 4.92 | 61.2702366127 | 8.03 | 16.905 | 5.85 | 171388 | 10.81705796 | CS |
52 | -0.64 | -4.7093451067 | 13.59 | 17.7 | 5.85 | 173044 | 11.96975936 | CS |
156 | -8.15 | -38.6255924171 | 21.1 | 21.98 | 5.85 | 184412 | 13.01435451 | CS |
260 | -8.15 | -38.6255924171 | 21.1 | 21.98 | 5.85 | 184412 | 13.01435451 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions